MariMed heads into its May 14 earnings report as one of the OTC cannabis sector's quieter short stories — but the stock's sharp one-month rally makes the print a genuine test of momentum.
The lending market tells a story of almost zero short-side pressure. Short interest has collapsed more than 70% over the past week to just 0.004% of the free float, a level that carries no meaningful signal of bearish conviction. Availability is near fully open, with the lending pool barely touched at all. Borrow costs have eased too — the cost to borrow has dropped to roughly 8%, down from above 11% in late April, and continues to trend lower. There is simply no evidence of a crowded short trade here.
The more interesting angle is price. MariMed climbed 20% in the past month to close at $0.084 on May 13, a run that puts it well ahead of its cannabis peers heading into the print. Close comparables all fell on the session — TRUL dropped nearly 5% on the day and 16% on the week, CL fell 4.4%, and CURA gave up almost 3%. The divergence is notable. MariMed's gain arrived while the broader cannabis cohort weakened, meaning the stock now enters earnings carrying relative outperformance that needs fundamental support.
The fundamental picture offers a mixed backdrop. Estimated revenues sit near $162 million, with EBITDA of approximately $17 million — a headline that looks constructive. But net debt of roughly $80 million and negative operating cash flow of around $5.3 million point to an ongoing balance sheet tension that bulls and bears circle around. Analyst coverage is thin and dated; the most recent formal analyst action on record dates to late 2023, so no fresh Street consensus frames this print in a meaningful way. The EPS surprise factor score ranks in the 75th percentile, suggesting the company has a decent recent track record of beating estimates — but with no current analyst model to beat against, the comparison is directional at best.
Insider activity over the past 90 days reflects routine award-and-sell patterns rather than any deliberate directional signal. The CEO Jon Levine received share awards in both April and May and sold small tranches — totalling under $3,000 in proceeds — consistent with tax-withholding mechanics rather than a conviction move. The COO and Chief Commercial Officer followed a near-identical pattern. Net insider activity over 90 days is nominally positive at roughly 78,000 shares, but the dollar value is negligible.
The print will test whether MariMed's one-month price surge is grounded in operational progress — specifically whether cash generation is improving and net debt is moving in the right direction — or whether it simply reflects sector rotation noise that the fundamentals do not yet support.
See the live data behind this article on ORTEX.
Open MRMD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
